Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Withdrawn 1Terminated 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 46Lymphoma, Non-Hodgkin 15Lymphoma 15Leukemia, B-Cell 14Leukemia 14Lymphoma, Follicular 11Recurrence 9Neoplasms 7Lymphoma, Large B-Cell, Diffuse 7Lymphoma, Mantle-Cell 6Precursor Cell Lymphoblastic Leukemia-Lymphoma 5Burkitt Lymphoma 5Lymphoma, B-Cell 4Bronchiolitis Obliterans Syndrome 4Waldenstrom Macroglobulinemia 3Lymphoma, B-Cell, Marginal Zone 3Hodgkin Disease 2Hematologic Neoplasms 2Thrombocytopenia 1Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 1Paraproteinemias 1Lymphocytosis 1Lymphadenopathy 1Leukemia, Prolymphocytic 1Leukemia, Lymphoid 1Fever 1Fatigue 1Disease 1Agammaglobulinemia 1

Interventions

Cyclophosphamide 40fludarabine 36fludarabine phosphate 28Tacrolimus 20Whole-Body Irradiation 18Mycophenolic Acid 18Busulfan 18Melphalan 16thymoglobulin 14Rituximab 13Antilymphocyte Serum 12venetoclax 11Thiotepa 10Nivolumab 9Methotrexate 9Granulocyte Colony-Stimulating Factor 9Stem Cell Transplantation 8Peripheral Blood Stem Cell Transplantation 8Cyclosporine 8trametinib 7Sirolimus 7Cytarabine 7Azacitidine 7AP 1903 reagent 7Filgrastim 6Dexamethasone 6aldesleukin 5Mesna 5Ipilimumab 5Interleukin-2 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Hematologic Neoplasms × ofatumumab × Lymphoid × Clear all
NCT01125787 2011-07-20

Clinical Protocol for the Treatment of Patients With Previously Untreated Chronic Lymphocytic Leukemia With a Combination of Bendamustine and Ofatumumab

Nevada Cancer Institute

Phase 2 Terminated
1 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Non-Hodgkin, Leukemia, Lymphocytic, Chronic, B-Cell, Hematologic Neoplasms

NCT01131247 2011-07-20

PH2 Trial in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) With a Combination of Bendamustine & Ofatumumab

Nevada Cancer Institute

Phase 2 Withdrawn
37 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Lymphoma, Lymphoma, Non-Hodgkin, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡